CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EBIT: As of FY2026 Q2, the actual value is USD -5.729 M.

Financial Overview: Second Quarter and First Half 2026

Cash and Working Capital

As of June 30, 2026, Cingulate Inc. reported $28.4 million in cash and cash equivalents, an increase from $11.0 million as of December 31, 2025. This increase was primarily driven by $12.0 million raised from a private placement and $19.0 million from At-the-Market Agreement and Purchase Agreement, partially offset by $12.8 million in cash used for operations. The company’s working capital was approximately $21.6 million as of June 30, 2026, an increase of $19.9 million compared to December 31, 2025.

Research and Development (R&D) Expenses

For the three months ended June 30, 2026, R&D expenses were $1.5 million, a 44.9% decrease from $2.7 million for the same period in 2025. For the six months ended June 30, 2026, R&D expenses were $3.7 million, a 25.4% decrease from $5.0 million in the first half of 2025.

Selling, General and Administrative (SG&A) Expenses

SG&A expenses for the three months ended June 30, 2026, were $3.9 million, an increase of 101.5% compared to $1.9 million for the same period in 2025. For the six months ended June 30, 2026, SG&A expenses rose to $9.7 million, an increase of 181.7% from $3.4 million in the first half of 2025.

Operating Loss

Operating loss for the three months ended June 30, 2026, was - $5.4 million, compared to - $4.6 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the operating loss was - $13.3 million, an increase from - $8.4 million for the six months ended June 30, 2025.

Net Loss

Net loss for the three months ended June 30, 2026, was - $5.9 million, compared to - $5.0 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, net loss was - $15.2 million, compared to - $8.8 million for the six months ended June 30, 2025.

Other Financial Data (Balance Sheet as of June 30, 2026)

• Total assets: $33.1 million.
• Total liabilities: $9.6 million.
• Accumulated deficit: - $147.6 million.
• Total stockholders’ equity: $23.5 million.

Outlook / Guidance

Cingulate Inc. anticipates that its current cash and cash equivalents of $28.4 million will be sufficient to fund operations into mid-2027. This funding is expected to cover costs for completing requested CMC work, seeking regulatory approval for CTx-1301, and continuing the build-out of commercial readiness capabilities. The company remains committed to resubmitting the NDA for CTx-1301 as promptly as practicable following the completion of CMC work.